【摘要】 目的 采用循證醫學的方法評價甘露聚糖肽聯合順鉑對比單用順鉑治療惡性胸腔積液的有效性和安全性。 方法 計算機檢索中國生物醫學文獻數據庫、中國期刊全文數據庫、中文科技期刊全文數據庫、萬方數據庫，收集甘露聚糖肽聯合順鉑對比單用順鉑治療惡性胸腔積液的隨機對照試驗，檢索時間為各數據庫建庫至2011年3月。對文獻進行質量評價，用RevMan 5.0軟件對數據進行Meta分析。 結果 共納入6項研究，所有文獻質量均為C級。共收入388例患者，Meta分析結果顯示甘露聚糖肽聯合順鉑組與單用順鉑組相比，總有效率前者高于后者，差異有統計學意義（Plt;0.05）；消化道不良反應發生率兩組組間差異無統計學意義（P=0.05）；骨髓抑制發生率前者低于后者，差異有統計學意義（Plt;0.05）；Karnofsky評分提高率前者高于后者，差異有統計學意義（Plt;0.05）。 結論 系統評價表明，甘露聚糖肽聯合順鉑治療惡性胸腔積液的療效優于單用順鉑的方案。【Abstract】 Objective To assess the clinical efficacy and safety of mannatide plus cisplatin treating malignant pleural effusion. Methods Literatures were retrieved from CBM, VIP, CNKI, Wanfang databases by computer. Literatures were enrolled according to inclusion and exclusion criteria, and the quality of studies was evaluated according to the Cochrane Library handbook. The period duration of searching was between the establishment of the databases and March, 2011. Meta-analysis was conducted by RevMan 5.0 software. Results The meta-analysis of 6 included RCT, all ranked C, which involved 388 patients. The Meta-analysis showed that the total effective rate in mannatide plus cisplatin group significantly differed from that in cisplatin group (P＜0.05). There were no significant difference in the adverse reaction of digestive tract between the two intervention groups (P=0.05). The adverse reaction of marrow depression inmannatide plus cisplatin group was much lower than that in cisplatin group (P＜0.05). The increase of KPS in mannatide plus cisplatin group was higher than that in cisplatin group (P＜0.05). Conclusions The analysis indicates mannatide plus cisplatin has a better effect on malignant pleural effusion than single cisplatin. However, the reliability of this review is affected by poor quality of included studies, and large-scale randomized controlled trials of high quality are needed to confirm the conclusions above.
目的系統評價甘露聚糖肽對反復呼吸道感染的臨床療效及免疫功能的影響。 方法計算機檢索TheCochrane Library（2013年第12期）、PubMed、EMbase、CNKI、CBM、VIP和WanFang Data，收集甘露聚糖肽預防或治療反復呼吸道感染的隨機對照試驗（RCT），檢索時限均為從建庫至2013年12月。由2位研究者按照納入與排除標準篩選文獻，提取數據和評價納入研究的方法學質量后，采用RevMan 5.1.0軟件進行Meta分析。 結果共納入18個研究，1 481例患者。與安慰劑組相比，甘露聚糖肽組在總有效率、提升T細胞水平和提升抗體水平上具有明顯優勢，差異有統計學意義（P＜0.05）；與左旋咪唑組相比，甘露聚糖肽組在有效率和提升T細胞水平方面具有明顯優勢（P＜0.05），但在提升抗體水平上與其相當，其差異無統計學意義。 結論甘露聚糖肽可顯著提高反復呼吸道感染的臨床療效和患者免疫功能。